Meiqi Shi

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

David R. Spigel, David Vicente, Tudor–Eliade Ciuleanu et al. · Annals of Oncology · 2021 · 263 citations · Full text

Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner

Xiaobing Qin, Shaorong Yu, Leilei Zhou et al. · International Journal of Nanomedicine · 2017 · 237 citations · Full text

Cisplatin Resistance, 5P-dependent Manner, Exosomes +15

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang, Lin Wu, Baolan Li et al. · Journal of Clinical Oncology · 2022 · 161 citations · Full text

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Martin Reck, David Vicente, Tudor–Eliade Ciuleanu et al. · Annals of Oncology · 2018 · 103 citations · Full text

A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.

Li Zhang, Meiqi Shi, Cheng Huang et al. · Journal of Clinical Oncology · 2012 · 70 citations

Placebo Arm, Oncology, Phase Ii +15